APA (7th ed.) Citation

Mascarenhas, L., DuBois, S. G., Albert, C. M., Bielack, S., Orbach, D., Federman, N., . . . Laetsch, T. W. (2025). Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors. Journal of clinical oncology, 43(10), . https://doi.org/10.1200/JCO.24.00848

Chicago Style (17th ed.) Citation

Mascarenhas, Leo, et al. "Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas and Related Mesenchymal Tumors." Journal of Clinical Oncology 43, no. 10 (2025). https://doi.org/10.1200/JCO.24.00848.

MLA (9th ed.) Citation

Mascarenhas, Leo, et al. "Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas and Related Mesenchymal Tumors." Journal of Clinical Oncology, vol. 43, no. 10, 2025, https://doi.org/10.1200/JCO.24.00848.